List view / Grid view
11 June 2018 | By PerkinElmer
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
Application note: Simultaneous dual phosphoprotein target analysis with Alpha Terbium SureFire Ultra Multiplex
This application note discusses how the Alpha SureFire® Ultra™ Multiplex technology provides a phosphoprotein multiplexing detection platform that is truly homogeneous and high throughput.
19 March 2018 | By Drug Target Review
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.
8 March 2018 | By Dr Zara Kassam (Drug Target Review)
Study of Drosophila links ceramide accumulation to heart dysfunction...
2 February 2018 | By Dr Zara Kassam (Drug Target Review)
Researchers discover molecular nets inside heart muscles which hold promise for new heart failure treatment...
2 February 2018 | By SMi Group
SMi Reports: SMi’s 2nd annual Drug Discovery conference, taking place in London on 21 and 22 March 2018, will discuss the role of artificial intelligence in drug discovery.
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
15 January 2018 | By BMG Labtech GmbH
Optimising the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems.Despite this, the kinetics of new receptor ligands are rarely measured early in the drug discovery process, largely because current assays are…
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative In vitro immuno-oncology screening platform
4 January 2018 | By IntelliCyt Corporation
In this webinar, speakers discussed how the IntelliCyt iQue Screener Plus platform is being utilised to deliver rich datasets for compound screening, target validation and is how it is transforming immuno-oncology.
Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
A significant amount of selectivity and potency data originating from screening of drug targets is generated each year and deposited in public databases. This can be exploited to accelerate drug discovery, in particular, for a variety of repurposing activities...